Prevention of cardiac surgery-associated acute kidney injury by risk stratification using (TIMP-2)*(IGFBP7)

Biomark Med. 2021 Oct;15(14):1201-1210. doi: 10.2217/bmm-2020-0656. Epub 2021 Sep 3.

Abstract

Aim: The purpose of this study was to assess urinary (TIMP-2)*(IGFBP7) for prevention of acute kidney injury (AKI) in patients undergoing elective cardiac surgery. Materials & methods: Two retrospective cohorts were analyzed before and after the implementation of urinary (TIMP-2)*(IGFBP7). The control cohort had a standard supportive care. For the (TIMP-2)*(IGFBP7) cohort, patients with the (TIMP-2)*(IGFBP7) >0.3 received renal supportive measures. Results: A total of 382 patients were included, 197 in the control cohort and 185 in intervention cohort. The incidence of AKI was significantly reduced in the (TIMP-2)*(IGFBP7) cohort (20.5 vs 29.9%, p < 0.05). In multivariate analysis, patients of the (TIMP-2)*(IGFBP7) cohort had a lower risk of developing AKI (p = 0.029). Conclusion: In conclusion, renal supporting care based on AKI risk stratification using urinary (TIMP-2)*(IGFBP7) may reduce AKI incidence.

Keywords: (TIMP-2)*(IGFBP7); AKI; acute kidney injury; cardiac surgery.

MeSH terms

  • Acute Kidney Injury / metabolism*
  • Aged
  • Biomarkers / metabolism
  • Cardiac Surgical Procedures / adverse effects*
  • Female
  • Humans
  • Kidney / metabolism
  • Male
  • Retrospective Studies
  • Risk Assessment
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism*

Substances

  • Biomarkers
  • TIMP2 protein, human
  • Tissue Inhibitor of Metalloproteinase-2